ascopubs.org

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

In all, 1,014 newly diagnosed CP-CML patients were randomly assigned to imatinib 800 mg/d (n = 338), imatinib 400 mg/d (n = 325), or imatinib 400 mg/d plus interferon alfa (IFN-α; n = 351). Dose ...
ascopubs.org

Assessment of early response to imatinib 800 mg after 400 mg progression by 18f-fluorodeoxyglucose positron emission tomography in patients with metastatic gastrointestinal ...

Efficacy of neoadjuvant doxorubicin and ifosfamide (AI) in myxoid/round cell liposarcoma (MRCL): The M. D. Anderson Cancer Center experience (MDACC). Background: Imatinib is the standard first-line ...
Nature

Does tumor mutational status correlate with clinical response to imatinib?

You have full access to this article via your institution. Gastrointestinal stromal tumors (GISTs) frequently harbor mutant KIT or PGFRA tyrosine kinases. Imatinib has induced good response rates and ...
Medscape

Long-Term Imatinib Extends Survival in High-Risk GIST

June 6, 2011 (Chicago, Illinois) — Extended adjuvant treatment with imatinib (Gleevec) improves survival in patients with high-risk gastrointestinal stromal tumors (GIST). Imatinib administered for 3 ...
Business Wire

Shorla Oncology Announces FDA Approval of IMKELDI (imatinib) Oral Solution, an Oral Liquid for the Treatment of Certain Forms of Leukemia and Other Cancers

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the first ...
EurekAlert!

EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST

Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST ...